
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4513935/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D. Journal of Nephrology, 2022, 35, 863-873.	2.0	10
2	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacological Research, 2022, 175, 105997.	7.1	43
3	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum (2012), 2022, 113, 295-350.	0.9	3
4	The effects of CHF6467, a new mutated form of NGF, on cell models of human glioblastoma. A comparison with wild-type NGF. Growth Factors, 2022, 40, 37-45.	1.7	2
5	Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature. Frontiers in Pharmacology, 2022, 13, .	3.5	1
6	Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials. Journal of Clinical Pharmacology, 2021, 61, 810-819.	2.0	11
7	Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 375-384.	1.6	1
8	Cell-of-Origin and Genetic, Epigenetic, and Microenvironmental Factors Contribute to the Intra-Tumoral Heterogeneity of Pediatric Intracranial Ependymoma. Cancers, 2021, 13, 6100.	3.7	4
9	Beyond antibodies: ankyrins and DARPins. From basic research to drug approval. Current Opinion in Pharmacology, 2020, 51, 93-101.	3.5	16
10	Development of an UPLC-MS/MS Method for Quantitative Analysis of Clotrimazole in Human Plasma Samples. Separations, 2020, 7, 62.	2.4	1
11	A proof-of-concept study on CCRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB. Journal of Headache and Pain, 2020, 21, 124.	6.0	7
12	PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation. International Journal of Molecular Sciences, 2020, 21, 8214.	4.1	25
13	Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. International Journal of Molecular Sciences, 2020, 21, 8242.	4.1	82
14	P2X7 receptors exert a permissive effect on the activation of presynaptic AMPA receptors in rat trigeminal caudal nucleus glutamatergic nerve terminals. Journal of Headache and Pain, 2020, 21, 83.	6.0	12
15	DNA inhibitors for the treatment of brain tumors. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 195-207.	3.3	3
16	A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials. European Journal of Clinical Pharmacology, 2020, 76, 1083-1092.	1.9	11
17	Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Annals of Intensive Care, 2020, 10, 94.	4.6	36
18	Vascular endothelial growth factor receptor 1 in glioblastoma‑associated microglia/macrophages. Oncology Reports, 2020, 43, 2083-2092.	2.6	10

#	Article	IF	CITATIONS
19	Tigecycline pharmacokinetics in critically ill patients on renal replacement therapy: possible warnings and potential perspectives for the research agenda. Annals of Intensive Care, 2020, 10, 141.	4.6	1
20	Aspirin inhibits proliferation and promotes differentiation of neuroblastoma cells via p21 Waf1 protein upâ€regulation and Rb1 pathway modulation. Journal of Cellular and Molecular Medicine, 2019, 23, 7078-7087.	3.6	9
21	When innovation goes fast. The case of hemophilia. Current Opinion in Pharmacology, 2019, 45, 95-101.	3.5	5
22	Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation. Journal of Cellular Physiology, 2019, 234, 15459-15471.	4.1	19
23	Phospho-mTOR expression in human glioblastoma microglia-macrophage cells. Neurochemistry International, 2019, 129, 104485.	3.8	17
24	Pro-Inflammatory Activation of a New Immortalized Human Microglia Cell Line. Brain Sciences, 2019, 9, 111.	2.3	21
25	Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. Peptides, 2019, 116, 16-21.	2.4	22
26	Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer. Clinical Therapeutics, 2019, 41, 982-991.	2.5	1
27	Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation. , 2019, 234, 15459.		1
28	The mTOR kinase inhibitor rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human microglial cells. EXCLI Journal, 2019, 18, 779-798.	0.7	12
29	The process of drug discovery and the Yin/Yang of small-molecule/biotech option. Microchemical Journal, 2018, 136, 139-142.	4.5	0
30	Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro. Journal of Headache and Pain, 2018, 19, 107.	6.0	15
31	Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®. Neurology and Therapy, 2018, 7, 391-393.	3.2	Ο
32	The human microglial HMC3 cell line: where do we stand? A systematic literature review. Journal of Neuroinflammation, 2018, 15, 259.	7.2	138
33	Diffusion of complementary evolving pharmaceutical innovations: The case of Abacavir and its pharmacogenetic companion diagnostic in Italy. Technological Forecasting and Social Change, 2018, 134, 223-233.	11.6	5
34	Interactions between integrase inhibitors and human arginase 1. Journal of Neurochemistry, 2017, 142, 153-159.	3.9	4
35	Blockade of CCR5 receptor prevents M2 microglia phenotype in a microglia-glioma paradigm. Neurochemistry International, 2017, 108, 100-108.	3.8	43
36	The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. Journal of Experimental and Clinical Cancer Research, 2017, 36, 106.	8.6	36

#	Article	IF	CITATIONS
37	A Comprehensive Review on Copemyl®. Neurology and Therapy, 2017, 6, 161-173.	3.2	6
38	PP077 Intravitreal Corticosteroids In Macular Edema: Quality Of The Evidence. International Journal of Technology Assessment in Health Care, 2017, 33, 107-108.	0.5	0
39	Optimal Solubility of Diclofenac <i>β</i> -Cyclodextrin in Combination with Local Anaesthetics for Mesotherapy Applications. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-8.	1.2	5
40	Corticosteroidi per via Intravitreale per il Trattamento Dell'edema Maculare: Revisione e Valutazione Della Qualità Dell'evidenza. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000251.	0.1	0
41	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS ONE, 2017, 12, e0187393.	2.5	11
42	Exploiting Microglial Functions for the Treatment of Glioblastoma. Current Cancer Drug Targets, 2017, 17, 267-281.	1.6	40
43	Macrophages/microglia in glioblastoma: a Zelig-like story of changing phenotypes. Translational Cancer Research, 2017, 6, S1101-S1103.	1.0	Ο
44	mTOR in Multiple Sclerosis. , 2016, , 331-343.		5
45	Antiretrovirals inhibit arginase in human microglia. Journal of Neurochemistry, 2016, 136, 363-372.	3.9	15
46	Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients. AIDS Research and Human Retroviruses, 2016, 32, 654-657.	1.1	7
47	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. Infectious Diseases, 2016, 48, 48-55.	2.8	5
48	First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing. Journal of Clinical Virology, 2016, 78, 1-3.	3.1	4
49	The analgesic agent tapentadol inhibits calcitonin gene-related peptide release from isolated rat brainstem via a serotonergic mechanism. Life Sciences, 2016, 145, 161-165.	4.3	8
50	mTOR Kinase: A Possible Pharmacological Target in the Management of Chronic Pain. BioMed Research International, 2015, 2015, 1-13.	1.9	54
51	The activation of type 1 corticotropin releasing factor receptor (CRF-R1) inhibits proliferation and promotes differentiation of neuroblastoma cells in vitro via p27Kip1 protein up-regulation and c-Myc mRNA down-regulation. Molecular and Cellular Endocrinology, 2015, 412, 205-215.	3.2	7
52	The free fractions of circulating docosahexaenoic acid and eicosapentenoic acid as optimal end-point of measure in bioavailability studies on n-3 fatty acids. Prostaglandins Leukotrienes and Essential Fatty Acids, 2015, 96, 11-16.	2.2	4
53	The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype. Journal of Neuroinflammation, 2014, 11, 125.	7.2	54
54	Proinflammatory-Activated Glioma Cells Induce a Switch in Microglial Polarization and Activation Status, From a Predominant M2b Phenotype to a Mixture of M1 and M2a/B Polarized Cells. ASN Neuro, 2014, 6, AN20130045.	2.7	67

#	Article	IF	CITATIONS
55	Antiretroviral agents increase NO production in gp120/IFNÎ ³ -stimulated cultures of rat microglia via an arginase-dependent mechanism. Journal of Neuroimmunology, 2014, 266, 24-32.	2.3	16
56	Tapentadol inhibits calcitonin gene-related peptide release from rat brainstem in vitro. Peptides, 2014, 56, 8-13.	2.4	9
57	Hydroxyurea induces vasopressin release and cytokine gene expression in the rat hypothalamus. Journal of Neuroimmunology, 2006, 179, 94-100.	2.3	2
58	Pharmacokinetics of Cyclosporin Microemulsion in Patients with Inflammatory Bowel Disease. Clinical Pharmacokinetics, 2001, 40, 473-483.	3.5	27
59	The Heme Oxygenase-Carbon Monoxide Pathway in the Control of Neuroendocrine Function. , 2001, 29, 108-116.		3
60	The Roles of Carbon Monoxide and Nitric Oxide in the Control of the Neuroendocrine Stress Response: Complementary or Redundant. Stress, 2001, 4, 3-11.	1.8	1
61	Endothelins Enhance Prostaglandin (PGE2 and PGF2α) Biosynthesis and Release by Human Luteal Cells: Evidence of a New Paracrine/Autocrine Regulation of Luteal Function. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 811-817.	3.6	29
62	The Generation of Nitric Oxide and Carbon Monoxide Produces Opposite Effects on the Release of Immunoreactive Interleukin-1Â from the Rat Hypothalamus in Vitro: Evidence for the Involvement of Different Signaling Pathways. Endocrinology, 1998, 139, 1031-1037.	2.8	19